Dual-Phase Release Finasteride-Loaded Microspheres for Androgenetic Alopecia Treatment: Rapid Intervention and Sustained Control of Dihydrotestosterone

This study found that extracellular vesicles derived from hyaluronic acid-stimulated induced pluripotent stem cells significantly improved hair growth in a model of androgenetic alopecia in mice by enhancing Wnt/β-catenin signaling and regulating androgen receptor activity, showing comparable results to the commonly used treatment finasteride.

The study investigated immune cell patterns around the hair follicle infundibulum in androgenetic alopecia, revealing significant differences in immune signatures between patients with AGA and control donors, specifically noting an enrichment of CD4 cells in the patient group.

This review discusses current and emerging therapies for androgenetic alopecia, emphasizing regenerative treatments and nanotechnology advancements, but it reports no new clinical results.

In a study using an AGA mouse model, researchers observed that a novel topical gel combining hybrid extracellular vesicles, gold nanoparticles, and finasteride accelerated hair regrowth and improved hair quality more effectively than conventional minoxidil treatment, presenting a promising option with fewer side effects.

This study investigated the potential mechanisms of Curcuma aeruginosa in treating androgenetic alopecia and identified 66 bioactive compounds interacting with proteins involved in the disorder, suggesting its involvement in hormone response and specific signaling pathways.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.

This study found that finasteride niosomes may enhance hair follicle drug accumulation and promote hair regeneration in androgenetic alopecia mice more effectively than current finasteride formulations.

This review examines current and potential tissue engineering strategies for hair follicle regeneration in androgenetic alopecia but does not provide new clinical results, highlighting the need for further research and development.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study found that Paeonia lactiflora and Poria cocos extracts promoted hair regrowth in a mouse model of androgenetic alopecia, with similar effects observed to normal controls.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This study found that male pattern baldness in European males is strongly heritable and associated with genetic markers linked to earlier puberty, bone density, and pancreatic function.

This review explores recent findings on the roles of melanocyte and melanocyte stem cells in the hair follicle, highlighting their importance for skin health and potential applications in regenerative medicine, but reports no new clinical results.

This study reports that while topical minoxidil treatment showed a response in less than 40% of men after 24 weeks, oral finasteride stopped hair loss in over 80% of patients at 12 months; perceived sexual side effects of the latter may limit its use.

This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.